A Photographer’s Rare Blood Cancer Symptoms Come to Life Through Generative AI
Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
Targeted Oncology1d
Next-Generation Approaches and Future Directions in PV Care
A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) ...
The American Journal of Managed Care6d
Understanding Hematocrit Thresholds in Polycythemia Vera Treatment
Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...
BioSpace13d
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Physician's Weekly4d
Shaping the Future of PV Treatment Through Molecular Understanding
Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...
Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight
The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population ...
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...
Business Wire5d
Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a ...